• a significant mental status change, not due to a metabolic disorder (e.g., delirium), that has not responded to treatment • a significant behavioral change, significant memory loss or brain injury and a reasonable suspicion of ANY of the following:
• autism spectrum disorder • brain tumor • cerebral anoxic or hypoxic episode • central nervous system (CNS) infection with presence of neurocognitive problems (e.g., herpes encephalitis, human immunodeficiency virus [HIV] infection, Lyme disease with CNS neurological involvement) • dementia (e.g., Alzheimer's disease, vascular dementia, Lewy body dementia) • demyelinating disease (e.g., multiple sclerosis) • epilepsy and seizure disorders • exposure to agents known to be associated with cerebral dysfunction (e.g., lead poisoning, intrathecal methotrexate, cranial irradiation) • extrapyramidal disease (e.g., Parkinson's, Huntington's Disease) • postconcussion syndrome • stroke or cerebral vascular injury (e.g., brain aneurysm, subdural hematoma) • traumatic brain injury • concussion (mild traumatic brain injury) and mild cognitive impairment (neurocognitive disorder) when those diagnoses are associated with a change in mental status, there is also a suspicion of an underlying central nervous system condition and standard treatment has failed Neuropsychological testing is considered to be not medically necessary when used primarily for:
• educational or vocational assessment or training • improving academic performance • baseline assessment of function • monitoring of chronic conditions when there is no significant new change in behavior, mental state or cognition • screening purposes Computerized neuropsychological testing for any indication that does not require a physician, psychologist, or licensed mental health professional to provide interpretation and preparation of a report is considered experimental, investigational or unproven.
General Background
Neuropsychological testing consists of the administration of a series of standardized assessments designed to objectively measure cognitive function. Neuropsychological testing is indicated when notable behavioral and/or cognitive changes have been associated with a history of moderate to severe head trauma or organic brain disease. This testing provides the basis for the conclusions regarding the neurocognitive effects of various medical disorders and aids in diagnosis. Making an assessment of preserved and compromised cognitive functions can also help to predict the effects of remediation. The testing results assist the clinician determine the scope and severity of cognitive impairments through a comparison of patient responses to established normative test values. The results of the testing may assist the clinician in developing a program or plan of care that is specific to the patient's needs, and determine appropriate adjustments to the patient's treatment.
Neuropsychological testing should be delayed until reversible medical or metabolic conditions that are adversely affecting the central nervous system (CNS) are corrected, when possible. Formal neuropsychological testing should also be delayed until any acute changes have stabilized following trauma, infections, or metabolic or vascular insults to the CNS.
Neuropsychological testing should only be performed by practitioners who are appropriately trained in administering and interpreting these tests.
The components of neuropsychological assessment include all of the following:
• assessment of higher cortical functions, which includes thought process and organization, reasoning and judgment • assessment of attention, language, memory and problem-solving • obtaining a developmental history, the history of medical disease, trauma and psychiatric illness, and the history of the person's cognitive decline and/or premorbid level of function Neuropsychological tests and measures used for clinical purposes must meet standards for psychometric adequacy. These standards include (American Academy of Clinical Neuropsychology [AACN], 2007):
• acceptable levels of reliability • demonstrated validity in relation to other tests and/or to brain status, including evidence that the test or measure assesses the process, ability, or trait it purports to assess • normative standards that allow the clinician to evaluate the patient's scores in relation to relevant patient characteristics, such as age, gender, and socio-demographic or cultural/linguistic background Neuropsychological testing differs from psychological testing in that neuropsychological testing measures higher cerebral functioning, which focuses on cognitive skills and abilities (i.e., language, memory and problem-solving), whereas psychological testing is designed to provide information about a patient's personality and emotional functioning. Types of psychological testing include self-reported questionnaires, rating scales (e.g., the Hamilton Depression Rating Scale), projective techniques (e.g., the Rorschach or Thematic Apperception Test [TAT]), and screening tests of cognitive function.
Testing Methods
A wide variety of neuropsychological tests are available. These tests have been validated, are reliable and sensitive, and have been standardized to a normative sample. Normative data provides information about the expected test performance of individuals within a particular group, which is often stratified based on age or level of education (Hill, et al., 2016) . The fundamental core neuropsychological assessment typically includes tests designed to measure attention, concentration, learning, memory, problem-solving, language function, and visualspatial function.
The two basic approaches to testing include a fixed or a flexible battery. The fixed battery approach requires that the same tests are administered to every patient in a standardized manner. One example of a fixed battery is the Halstead-Reitan battery (Hill, et al., 2016) . An advantage to the fixed battery approach is that the information gathered is comprehensive and systematically assesses multiple domains of cognitive functioning. Disadvantages the fixed battery approach include its length which may be too long for some patients to tolerate. In contrast, the flexible battery approach allows neuropsychologists to develop a test battery based on the referral question, patient's history, and clinical interview (Hill, et al., 2016) . In this approach, a brief set of basic tests is initially administered, and additional tests of more specific abilities are used to conduct in-depth follow-up assessments based on each particular patient's needs.
Computerized Neuropsychological Testing:
Computerized neuropsychological testing is also referred to as automated or computer-based testing. This type of testing has been developed over the last 20 years (Schatz and Browndyke, 2002) as an alternative, or adjunct to, traditionally administered testing methods. There are features in computer-based testing that are absent in the traditional form of neuropsychological testing, including: timing of response latencies, automated analysis of response patterns, transfer of results to a database for further analysis, and the ease with which normative data can be collated or compared to existing databases (Schatz and Browndyke, 2002) . Limitations to computer-based testing include, but may not be limited to: unfamiliarity with the equipment by the patient and the potential for inaccurate timing procedures. Some of the tests are a translation of existing standardized tests into a computerized administration (e.g., Wisconsin Card Sorting Test ™ ) while others include the development of tests and test batteries of tests unique to the computer application (Wild, et al., 2008) .
Many of the computer based tests were developed to evaluate the presence of mild cognitive impairment or for sports-related concussion. Some of the tests have been adapted for testing in the pediatric populations, including assessment for attention-deficit/hyperactivity disorder (ADHD) (Luciana, 2003) . These tests are also used in the research setting.
Many computerized tests do not require a professional to interpret or to complete a report. The computer program provides an automatically generated report. The test may not involve a visit or evaluation by a neuropsychologist and may be administered by a non-skilled or unlicensed individual. 
Neuropsychological Testing in the Educational Setting
Neuropsychological testing is also used in educational settings to provide information regarding educational planning and determine appropriate classroom placement (Stebbins, 2007) . The testing may be used to identify specific learning disabilities and developmental disabilities.
Neuropsychological Testing Migraines
The published literature regarding the clinical utility of neuropsychological testing for patients with headaches and migraines is not conclusive. It has been suggested that there may be cognitive impairment with migraines, but studies have not been conclusive (O'Bryant, et al., 2006; Baars, et al., 2010) .There is insufficient clinical evidence that demonstrates that neuropsychological testing is useful in clinical decision making or will improve management of these conditions.
Mild Cognitive Impairment (MCI)
Mild cognitive impairment (MCI) is a stage between normal cognitive changes that may occur with age and more serious symptoms that indicate dementia. Symptoms of MCI can include problems with thinking, judgment, memory, and language, but the loss doesn't significantly interfere with the ability to handle everyday activities. Symptoms of MCI include mild memory loss; difficulty with planning or organization; trouble finding words; frequently losing or misplacing things; and forgetting names, conversations, and events. An individual with MCI may be at greater risk of eventually developing Alzheimer's or another type of dementia, particularly if the degree of memory impairment is significant, but MCI does not always progress to dementia. Symptoms may remain stable for several years, and even improve over time in some people (National Institute of Neurological Disorders and Stroke [NINDS], 2018).
Chronic Fatigue Syndrome
Chronic fatigue syndrome (CFS) can be a disabling illness characterized by persistent fatigue and associated myalgias, tender lymph nodes, arthralgias, chills, feverish feelings and postexertional malaise. Diagnosis of this syndrome is by exclusion with no definitive laboratory test or physical findings. Evaluation for this condition should include a detailed medical history, complete physical examination, including a mental status examination and a standard series of urine and blood laboratory tests to identify other possible causes of illness. The medical necessity for the use of neuropsychological testing in the assessment and/or management of chronic fatigue syndrome is not supported in the medical literature.
Baseline Assessment
A recent area of development for neuropsychological testing, in particular computerized testing, is baseline assessment, which is when the testing is performed in the in the absence of signs and/or symptoms for purposes of a later comparison. A use for baseline testing that is becoming prevalent is in the assessment and management of sports-related concussion (Schatz and Browndyke, 2002) . In some contact sports, an athletic program may perform a baseline assessment of an individual's cognitive performance at the beginning of the season for purposes of later comparison in the event of an injury. When these tests are performed prior to injury, or in the absence of signs and/or symptoms, this use would not be considered medically necessary.
Concussion
A mild or minor traumatic brain injury (TBI) is a temporary and brief interruption of neurologic function after head trauma, and may involve a loss of consciousness. A concussion is a type of minor TBI usually caused by acceleration-deceleration or rotational injury to a freely mobile head, and is frequently associated with contact sports. Almost all-patients with minor TBI will have rapid and complete symptom resolution; with no long-term sequelae. The majority (80-90%) of concussions resolve in a short (7-10 day) period, although the recovery time frame may be longer in children and adolescents (McCrory, et al., 2013) .
The diagnosis of acute concussion involves the assessment of a range of domains, including clinical symptoms, physical signs, behavior, balance, sleep, and cognition, along with a detailed concussion history (McCrory, et al., 2009 ). The cornerstone of concussion management is physical and cognitive rest until symptoms resolve and then a graded program of exertion prior to medical clearance and return to play (when associated with sports injury). The majority of patients will recover spontaneously over several days (McCrory, et al., 2009 ). The individual should be completely symptom free at rest and with physical exertion (e.g., sprints, non-contact aerobic activity) and cognitive exertion (e.g., studying, schoolwork) prior to return to sports or recreational activities (CDC, 2019).
Past history of concussions is among the risk factors that can lead to a protracted period of recovery. The number and date(s) of prior concussions and the duration of symptoms for each injury should be assessed. The effects of multiple mild TBIs may be cumulative, especially if there is minimal duration of time between injuries and less biomechanical force results in subsequent mild traumatic brain injury (CDC, 2019).
Neuropsychological testing is increasingly being used in the area of sport-related concussion to assist in return to play decisions (McCrory, et al., 2009 ).The question as to whether or not routine testing is associated with improved clinical outcomes is unclear (Kirkwood, et al., 2009) . A review of the evidence for the clinical utility of a computerized test, ImPACT, reveals insufficient support to suggest that use of the test is associated with modified risk. The report concluded that "for evaluating and advising concussed athletes when to return to play, ImPACT test results should not be the determining factor (Mayers, et al., 2012) .
The effects of multiple mild TBIs may be cumulative. Risk factors for protracted recovery or cumulative impact include past history of concussion, time to recovery, successive concussions with limited time in between insults, and the degree of biomechanical force associated with the trauma (CDC, 2019). Therefore, a thorough clinical review that includes the number and date(s) of prior concussions is essential to a good assessment.
Neuropsychological testing may be medically necessary when the concussion is associated with a change in mental status, there is also a suspicion of an underlying central nervous system condition and standard treatment has failed.
Postconcussion Syndrome:
A small percentage of patients may report persistent symptoms (e.g., headache, sensory sensitivity, memory or concentration difficulties, irritability, sleep disturbance, depression) for extended periods after trauma. These symptoms are referred to as postconcussion or postconcussive syndrome (Heegaard and Biros, 2014) . The postconcussion syndrome (PCS) is a common sequelae of traumatic brain injury (TBI), and it is a symptom complex that includes headache, dizziness, neuropsychiatric symptoms, and cognitive impairment. PCS is most often described in the setting of mild TBI, but it may also occur after moderate and severe TBI, and similar symptoms are described after whiplash injuries as well. 
Literature Review-Computerized Neuropsychological Testing for Concussion:
Although neuropsychological testing appears to be used in the assessment of sport-related concussion, the scientific literature is not conclusive regarding the clinical utility of this testing for evaluation and management of concussion. The published literature generally addresses the use of computerized testing for the assessment of sport-related concussion in the areas of baseline assessment and return-to-play decisions. The studies focus on a specific population and it is difficult to generalize the results to other populations.
Hayes published a technology report for computerized neurocognitive testing (CNT) for sports-related head injury (Hayes, 2014; . The review included six studies that evaluated the ability of CNT to detect impairment due to sports-related concussion in athletes. All six studies used the ImPACT test; and, one study also evaluated HeadMinder. The review found that the overall body of evidence evaluating the diagnostic performance of CNT was of low quality. The review identified limitations of the evidence that included study quality, small number of studies, and the limited generalizability of the findings to female populations. The review concluded that it appears that computerized neurocognitive testing (CNT) improves clinical assessment of cognitive impairment in athletes with a concussion; however, it is uncertain what the extent of the clinical benefit added by CNT, its role in patient management, and the impact on health outcomes. The report included the following findings:
• CNT combined with clinical assessment has good sensitivity and moderate specificity for the diagnosis of concussion. • Evidence is lacking evaluating the prognostic ability of CNT for evaluating recovery from concussion.
• Evidence is lacking evaluating the effect of CNT on post-assessment symptoms.
• Evidence is lacking evaluating the accuracy of CNTs other than the ImPACT test. Broglio et al. (2018) reported on a study to evaluate the test-retest reliability of commonly implemented and emerging concussion assessment tools across a large nationally representative sample of student-athletes. The study included participants (n = 4874) from the Concussion Assessment, Research, and Education Consortium who completed annual baseline assessments on two or three occasions. Each assessment included measures of self-reported concussion symptoms, motor control, brief and extended neurocognitive function, reaction time, oculomotor/oculovestibular function, and quality of life. Consistency between years 1 and 2 and 1 and 3 were estimated using intraclass correlation coefficients or Kappa and effect sizes (Cohen's d). Clinical interpretation guidelines were also generated using confidence intervals to account for non-normally distributed data. The results noted that reliability for the self-reported concussion symptoms, motor control, and brief and extended neurocognitive assessments from year one to two ranged from 0.30 to 0.72 while effect sizes ranged from 0.01 to 0.28 (i.e., small). The reliability for these same measures ranged from 0.34 to 0.66 for the year 1-3 interval with effect sizes ranging from 0.05 to 0.42 (i.e., small to less than medium). The year 1-2 reliability for the reaction time, oculomotor/oculovestibular function, and quality-of-life measures ranged from 0.28 to 0.74 with effect sizes from 0.01 to 0.38 (i.e., small to less than medium effects). The authors concluded that the investigation noted less than optimal reliability for most common and emerging concussion assessment tools and they noted that despite this finding, their use is still necessitated by the absence of a gold standard diagnostic measure, with the ultimate goal of developing more refined and sound tools for clinical use. Davis, et al (2017) reported on a systematic review to evaluate the evidence regarding the management of sportrelated concussion (SRC) in children and adolescents. The eight subquestions included the effects of age on symptoms and outcome, normal and prolonged duration, the role of computerized neuropsychological tests (CNTs), the role of rest, and strategies for return to school and return to sport (RTSp). Studies were included if they were original research on SRC in children aged 5 years to 18 years, and excluded if they were review articles, or did not focus on childhood SRC. Twenty-three articles addressed the question of: Is CNT accurate for diagnosing and assessing recovery of SRC concussion in children? Regarding CNT, the review concluded that the widespread routine use of baseline CNT is not recommended. Farnsworth et al. (2017) analyzed reliability data for computerized neurocognitive tests (CNTs) using metaanalysis and examine moderating factors that may influence reliability. Studies were included if they met all of the following criteria: used a test-retest design, involved at least one CNT, provided sufficient statistical data to allow for effect-size calculation, and were published in English. The review included eighteen studies involving 2674 participants. Intraclass correlation coefficients were extracted to calculate effect sizes and determine overall reliability. The Fisher Z transformation adjusted for sampling error associated with averaging correlations. Moderator analyses were conducted to evaluate the effects of the length of the test-retest interval, intraclass correlation coefficient model selection, participant demographics, and study design on reliability. Heterogeneity was evaluated using the Cochran Q statistic. The results included that the proportion of acceptable outcomes was greatest for the Axon Sports CogState Test (75%) and lowest for the ImPACT (25%). Moderator analyses indicated that the type of intraclass correlation coefficient model used significantly influenced effect-size estimates, accounting for 17% of the variation in reliability. The authors concluded that the Axon Sports CogState Test, which has a higher proportion of acceptable outcomes and shorter test duration relative to other CNTs, may be a reliable option; however, future studies are needed to compare the diagnostic accuracy of these instruments.
Gaudet et al. (2017) reported on a systematic review of existing research that investigated the prevalence of invalid baseline results and the effectiveness of Immediate Post-Concussion and Cognitive Testing (ImPACT)
embedded invalidity indicators in detecting suspect effort. The study included 17 studies that included prevalence rates of invalid performances or examined the effectiveness of ImPACT's invalidity indicators. The inclusion criteria included a minimum sample of at least 20 participants; included an original data-set; the study was relational, experimental, or quasi-experimental; the use of ImPACT for cognitive screening; and, the study included the rate of invalid performances generated for the study sample, even if not the primary focus of the study. Of these studies, 12 included prevalence rates of invalid baseline results; and across this group of studies (after removing an outlier), the weighted prevalence rate of invalid baseline results was 6%. Four of the 17 studies examined the effectiveness of ImPACT's embedded invalidity indicators. ImPACT's embedded invalidity indicators correctly identified suboptimal effort in approximately 80% of individuals instructed to perform poorly and avoid detection ('coached') or instructed to perform poorly ('naïve'). The authors concluded that the findings raise a number of issues pertaining to the use of ImPACT including that invalid performance incidence may increase with large group versus individual administration, use in nonclinical settings, and among those with Attention Deficit-Hyperactivity Disorder or learning disability. The authors note that although ImPACT's embedded invalidity indicators detect invalid performance at a rate of 6% on average, known group validity studies suggest that these measures miss invalid performance approximately 20% of the time when individuals purposefully underperform. Limitation of the studies included the small sample size. Hang et al. (2015) reported on a prospective cohort study to determine if computerized neurocognitive testing (Immediate Post-Concussion Assessment and Cognitive Testing [ImPACT]) in the emergency department (ED) can be used as a prognostic tool to detect young athletes at risk of having protracted concussive symptoms. The study included 109 subjects 11 to 18 years who presented to an ED less than 24 hours after sustaining a sportsrelated concussion. ImPACT was administered in the ED, and categorization of performance was done with score of "poor" if the athlete had 3 (of 4) or greater low domain scores. Participants completed the Post-Concussion Symptom Scale (PCSS) in the ED and at one and two weeks after injury. Athletes were symptomatic if their PCSS score was more than six in males and more than eight in females. Results indicated that 60% and 36% remained symptomatic at 1 and 2 weeks after injury, respectively. "Poor" ImPACT performance was not found to be particularly useful in predicting athletes with protracted symptoms (at 1 week: positive predictive value, 70.8%; negative predictive value, 43.5%; at 2 weeks: positive predictive value, 47.8%; negative predictive value, 68.9%). In bivariate analysis, a higher ED PCSS score was associated with protracted symptoms (at 1 week: odds ratio, 1.1 [confidence interval, 1.0-1.1]; at 2 weeks: odds ratio, 1.0 [confidence interval, 1.0-1.1]). The authors concluded that computerized neurocognitive testing in the ED has limited usefulness in predicting protracted symptoms and further research is necessary.
The American Academy of Clinical Neuropsychology (AACN) and the National Academy of Neuropsychology (NAN) published joint position paper on appropriate standards and conventions for computerized neuropsychological assessment devices (CNADs) (Bauer, et al., 2012) . The paper includes the following statements regarding CNADs:
• CNADs are subject to, and should meet, the same standards for the development and use of educational, psychological, and neuropsychological tests as are applied to examiner-administered tests. • Developers of CNADs are expected to provide a clear definition of the intended end-user population, including a description of the competencies and skills necessary for effective and accurate use of the device and the data it provides. • Test developers should provide users with sufficient technical information to insure that the local installation of a CNAD will produce data that can be accurately compared with that which exists in the test's normative database. • CNADs are subject to the same standards and conventions of psychometric test development, including descriptions of reliability, validity, and clinical utility (accuracy and diagnostic validity), as are examinerbased measures. • Professionals select scoring and interpretation services (including automated services) on the basis of evidence of the validity of the program and procedures as well as on other appropriate considerations • Professionals retain responsibility for the appropriate application, interpretation, and use of assessment instruments, whether they score and interpret such tests themselves or use automated or other services. Both groups completed ImPACT forms 1, 2, and 3, which were delivered sequentially either at: one week intervals for group one (n=46) or at baseline, day 45, and day 50 for group two (n=45). Group two also completed the Green Word Memory Test (WMT) as a measure of effort. Intraclass correlation coefficients (ICCs) were calculated for the composite scores of ImPACT between time points. Repeated-measures analysis of variance was used to evaluate changes in ImPACT and WMT results over time. The ICC values for group one ranged from 0.261-0.878 for the four ImPACT composite scores. The ICC values for group two ranged from 0.374-0.756. In group one, ImPACT classified 37.0% and 46.0% of healthy participants as impaired at time points two and three, respectively. In group two, ImPACT classified 22.2% and 28.9% of healthy participants as impaired at time points two and three respectively. ImPACT misclassified 22% to 46% of healthy college-aged adult sample as impaired on one or more indices at one or both time points after baseline testing. The authors note that ImPACT had varying test-retest reliability on several metrics using different time frames for reassessment. This study included healthy subjects, rather than those with a head injury, and did not address clinical utility.
Thomas et al. (2011) performed a prospective non-controlled study using sixty subjects, aged 11-17, who presented to the emergency department (ED) immediately after a head injury. The study was designed to answer two questions: 1) is there a correlation between performance on a computer-based neurocognitive assessment (ImPACT) performed within 12 hours of head injury, and repeat assessments performed at least once, from three to ten days later; and 2) was the computerized test more sensitive to the identification of concussion severity when compared to two standard clinical grading scales. Post-concussive symptoms, outcomes, and complications were assessed via telephone follow-up for all subjects. Sixty patients completed phone follow-up and only 36 patients (60%), however, completed follow-up testing. The median follow-up testing interval was six days post-injury. Traditional concussion grading was reported to not correlate with neurocognitive deficits detected in the ED or at follow-up. The neurocognitive domains of verbal memory, processing speed, and reaction time, on the other hand, were reported to show a correlation, though a statistical threshold for certainty or a statistical correlation was not reported. At two weeks post-injury, 23 patients (41%) had not returned to normal activity. At six weeks, six patients (10%) still had not returned to normal activity. No correlation with return to normal activity was reported. The authors concluded that immediate computerized neuropsychological assessment in the ED can predict neurocognitive deficits seen in follow-up. They further postulated that this information may be used to individualize treatment decisions. Limitations of the study included the small sample size, lack of control group, lack of power to identify a correlation between three days post injury, lack of power to perform a subgroup analysis, incomplete statistical reporting, and lack of comparison to the traditional validated and normed clinical neuropsychological test assessment. The study did not allow, nor draw, conclusions regarding the clinical utility of the intervention. It was noted that that the findings do not appear to be due to suboptimal effort or other factors related to poor test performance, since persons identified by individual programs as having poor baseline data were excluded from the analyses. The authors note that until the psychometric properties of these tests can be clarified, clinicians should use a battery of evaluative measures when assessing concussion. Findings from multiple assessment techniques, such as self-reported symptoms, postural control, and neurocognitive performance, should be incorporated into a concussion assessment protocol. The authors concluded that the neurocognitive evaluation should continue to be part of a multifaceted concussion assessment program, with priority given to those scores showing the highest reliability. Limitations of the study included the lack of comparison to standardized and normed tests, its focus on reportedly healthy subjects, rather than those with a head injury, and small sample size. In addition, the study was not designed to, and did not, address clinical utility.
Wild et al. (2008) conducted a systematic review of the status of computerized cognitive testing to detect cognitive decline in the aging population. Due to the heterogeneity across selected studies and test batteries, a quantitative meta-analysis was not possible. The study included review of 11 test batteries that were either developed to screen for cognitive decline in the elderly or have been applied to that indication. In all cases, published research was found that described psychometric properties of these tests. In slightly more than half the tests, normative data for elderly subjects were rated as less than adequate as a result of either small sample size or lack of data specific to older adults in a larger sample. It was noted that reliability data was typically presented in some form, although only three test batteries met the highest rating achieved by describing more than one type of reliability. Few of the batteries are fully self-administered-the tests ranged widely in the amount of interaction required of an examiner. One of the potential advantages of computerized tests is the flexibility in terms of immediate adjustment of performance levels. univariate analysis revealed all six measures contributed to the between-groups differences. A discriminant function analyses was conducted to measure the ability of the five ImPACT composite scores, as well as the PCSS to classify concussion status. One discriminant function was identified that consisted of the Visual Memory, Processing Speed, and Impulse Control composite scores PCSS, which correctly classified 85.5% of the cases. Approximately 82% of participants in the concussion group and 89% of participants in the control group were correctly classified. Using the data, the sensitivity of ImPACT was 81.9%, and the specificity was 89.4%. The investigators concluded that as part of a formal concussion management program, ImPACT may be a useful tool for the assessment of the neurocognitive and neurobehavioral sequelae of concussion, and may also provide post-injury cognitive and symptom data that can assist a practitioner in making return to play decisions. Limitations of the study included its lack of comparison to standardized and normed tests, its small sample size, and retrospective design. Further the study was not designed to, and did not, address clinical utility.
Repeat Testing
Repeat testing may be medically indicated when there is a significant change in behavior or medical condition and will affect treatment planning. Repeat testing for monitoring of a condition is not considered medically necessary unless it will impact clinical decision-making or level of care planning.
Neuropsychological Testing for Other Conditions
Neuropsychological testing is of limited value in any of the following conditions:
• When the patient has a substance abuse background and either of the following conditions apply:  The patient continues to use to an extent that would render test results inaccurate.  The patient is not yet 10 or more days post-detoxification. • When the patient is on certain daily medications (e.g., mood-altering substances or beta-blockers) that may confound interpretation of results, and the drug effects have not been ruled out
There are situations when routine screening of individuals is performed, such as for the purpose of early detection of changes in cognition. The use of neuropsychological testing for screening purposes, in the absence of signs and symptoms, would be considered not medically necessary. Regarding the question of diagnostic tools that are useful in identifying athletes suspected of having sustained concussion:
Professional Societies/Organizations-Concussion
• The reference standard by which these tools were compared was a clinician-diagnosed concussion (by physician or certified athletic trainer). It was noted that none of these tools is intended to "rule out" concussion or to be a substitute for more thorough medical, neurologic, or neuropsychological evaluations. • Regarding neuropsychological testing the guidelines note that, "Instruments for neuropsychological testing are divided into 2 types on the basis of their method of administration: paper-and-pencil and computer. Both types generally require a neuropsychologist for accurate interpretation, although they may be administered by a non-neuropsychologist. It is likely that neuropsychological testing of memory performance, reaction time, and speed of cognitive processing, regardless of whether administered by paper-and-pencil or computerized method, is useful in identifying the presence of concussion (sensitivity 71%-88% of athletes with concussion) (one Class II study; multiple Class III studies). There is insufficient evidence to support conclusions about the use of neuropsychological testing in identifying concussion in preadolescent age groups."
Recommendations related to assessment, diagnosis, and management of suspected concussion; and recommendations for management of diagnosed concussion (including acute management, return-to-play, and retirement):
• Regarding return-to-play (RTP) and concussion resolution: Clinical licensed health care providers (LHCPs) might use supplemental information, such as neurocognitive testing or other tools, to assist in determining concussion resolution. This may include but is not limited to resolution of symptoms as determined by standardized checklists and return to age-matched normative values or an individual's preinjury baseline performance on validated neurocognitive testing (Level C). • Regarding retirement from play after multiple concussions:
 LHCPs might refer professional athletes with a history of multiple concussions and subjective persistent neurobehavioral impairments for neurologic and neuropsychological assessment (Level C).  LCHPs caring for amateur athletes with a history of multiple concussions and subjective persistent neurobehavioral impairments might use formal neurologic/cognitive assessment to help guide retirement-from-play decisions (Level C).
Level C: Possibly effective, ineffective, or harmful (or possibly useful/predictive or not useful/predictive) for the given condition in the specified population. (Level C rating requires at least one Class II study or two consistent Class III studies.)
American Academy of Orthopaedic Surgeons (AAOS)
: the AAOS published a consensus statement regarding concussion (mild traumatic brain injury) and the team physician (2005/2011). Regarding neuropsychological (NP) testing, the guidelines include:
• It is essential that the team physician understand:  NP testing is recommended as an aid to clinical decision-making but not a requirement for concussion management.  NP testing is one component of the evaluation process and should not be used as a stand-alone tool to diagnose, manage or make return-to-play decisions in concussion. 
Recommendations for diagnosis of concussion include:
• Concussion remains a clinical diagnosis ideally made by a healthcare provider familiar with the athlete and knowledgeable in the recognition and evaluation of concussion. • Graded symptom checklists provide an objective tool for assessing a variety of symptoms related to concussions, while also tracking the severity of those symptoms over serial evaluations. • Standardized assessment tools provide a helpful structure for the evaluation of concussion, although limited validation of these assessment tools is available.
Recommendations for sideline evaluation and management of concussion include (Strength of recommendation C*):
• Any athlete suspected of having a concussion should be stopped from playing and assessed by a licensed healthcare provider trained in the evaluation and management of concussions. • Recognition and initial assessment of a concussion should be guided by a symptoms checklist, cognitive evaluation (including orientation, past and immediate memory, new learning and concentration), balance tests and further neurological physical examination.
• While standardized sideline tests are a useful framework for examination, the sensitivity, specificity, validity and reliability of these tests among different age groups, cultural groups and settings is largely undefined. Their practical usefulness with or without an individual baseline test is also largely unknown. • Balance disturbance is a specific indicator of a concussion, but not very sensitive. Balance testing on the sideline may be substantially different than baseline tests because of differences in shoe/cleat-type or surface, use of ankle tape or braces, or the presence of other lower extremity injury. • There is no same day return-to-play for an athlete diagnosed with a concussion.
• Athletes suspected or diagnosed with a concussion should be monitored for deteriorating physical or mental status.
Recommendations regarding neuropsychological testing include (Strength of recommendation C*):
• Neuropsychological (NP) tests are an objective measure of brain-behavior relationships and are more sensitive for subtle cognitive impairment than clinical exam. • Most concussions can be managed appropriately without the use of NP testing. • The majority (80-90%) of concussions resolve in a short (7-10 day) period, although the recovery time frame may be longer in children and adolescents • The cornerstone of concussion management is physical and cognitive rest until the acute symptoms resolve and then a graded program of exertion prior to medical clearance and return to play.
Regarding neuropsychological assessment, the guidelines include the following:
• The application of neuropsychological (NP) testing in concussion has been shown to be of clinical value and contributes significant information in concussion evaluation • NP assessment should not be the sole basis of management decisions. It should be seen as an aid to the clinical decision-making process in conjunction with a range of assessments of different clinical domains and investigational results. • Formal NP testing is not required for all athletes, however when this is considered necessary then it should ideally be performed by a trained neuropsychologist • NP testing may be used to assist return to play decisions and is typically performed when an athlete is clinically asymptomatic, however NP assessment may add important information in the early stages following injury
• There may be particular situations where testing is performed early to assist in determining aspects of management e.g., return to school in a pediatric athlete. This is usually best determined in consultation with a trained neuropsychologist • Baseline NP testing was considered by the panel and was not felt to be required as a mandatory aspect of every assessment, however may be helpful or add useful information to the overall interpretation of these tests. At present, there is insufficient evidence to recommend the widespread routine use of baseline neuropsychological testing.
These are consensus guidelines and it is not clear whether these conclusions are based on a methodologically rigorous systematic evaluation of the published evidence. The guidelines do not address the incremental clinical value of neuropsychological testing on health outcomes compared to the information that is available from clinical assessment. The guidelines do not address the clinical utility of testing once the symptoms have resolved. The clinical value that is referred to in the guidelines is related to sport concussion and return-to-play. The guidelines do not appear to demonstrate the clinical validity of neuropsychological testing for the evaluation of concussion.
Professional Societies/Organizations-Other Conditions American Academy of Child and Adolescent Psychiatry (AACAP):
The AACAP published practice parameters for the assessment and treatment of children and adolescents with ADHD (Pliszka, et al., 2007). Regarding neuropsychological testing the parameters note that this testing is not required as part of a routine assessment for ADHD, but may be indicated by the findings of the standard psychological assessment. The rationale for the recommendation notes that when screening or assessing for MCI, validated assessment tools should be used. Various instruments have acceptable diagnostic accuracy for detecting MCI, with no instrument being superior to another. Because brief cognitive assessment instruments are usually calibrated to maximize sensitivity rather than specificity, patients who test positive for MCI should then have further assessment (e.g., more indepth cognitive testing, such as neuropsychological testing with interpretation based on appropriate normative data) to formally assess for this diagnosis. Diagnosis of MCI is based ultimately on a clinical evaluation determining cognitive function and functional status and not solely on a specific test score.
In a practice parameter update on the evaluation and management of driving risk in dementia, the AAN states that there is insufficient evidence to recommend neuropsychological testing to predict driving capability among patients with dementia (Iverson et al. 2010 ).
The American Psychiatric Association published practice guidelines for treatment of patients with Alzheimer's disease and other dementias (American Psychiatric Association, 2007). The guidelines note that:
• Neuropsychological testing may help in deciding whether a patient with subtle or atypical symptoms actually has dementia as well as in more thoroughly characterizing an unusual symptom picture. • Testing may help to characterize the extent of cognitive impairment, to distinguish among the types of dementias, and to establish baseline cognitive function. • Testing may also help identify strengths and weaknesses that could guide expectations for the patient, direct interventions to improve overall function, assist with communication, and inform capacity determinations.
The guidelines notes that mild cognitive impairment is a term used to represent a variety of mild cognitive syndromes manifested by a modest but detectable decline in cognitive function in the setting of largely intact functional status (American Psychiatric Association, 2007). There are a variety of research definitions for mild cognitive impairment, but there is no consensus on the optimal definition. The most widely accepted definition requires the following:
• subjective cognitive complaints • evidence of objective deficits in cognitive function based on age-and education-adjusted norms on standardized neuropsychological tests • intact daily functioning, • evidence of cognitive decline from a prior level • evidence of not meeting the criteria for dementia American Psychological Association: the American Psychological Association published updated guidelines for the evaluation of dementia and age-related cognitive change (American Psychological Association, 2011). The guidelines include the following regarding neuropsychological testing for this condition:
• Neuropsychological evaluation and cognitive testing remain among the most effective differential diagnostic methods in discriminating pathophysiological dementia from age-related cognitive decline, cognitive difficulties that are depression-related, and other related disorders • Comprehensive neuropsychological evaluations for dementia and cognitive change include tests of multiple cognitive domains, typically including memory, attention, perceptual and motor skills, language, visuospatial abilities, reasoning, and executive functions. Measures of mood and personality may be relevant in many cases. Psychologists are encouraged to refer to current compendia resources and the clinical research literature in selecting assessment instruments. • Technology assisted assessments (e.g., computer administered cognitive batteries, tele-health visits) are rapidly advancing but appropriate psychometric properties and normative data are nascent. These technologies may have significant advantages for older persons with limited mobility or health-care access, but may also disadvantage older persons with limited experience and expertise interacting with technology. • Psychologists are encouraged to use standardized, reliable, and valid tests. Whether traditional or technology-assisted, appropriate tests have normative data for the age range of the person being assessed and are suitable for the individual's ethnicity, race, and educational background. In particular, the positive and negative predictive values of the instruments are considered when selecting tests for dementia, cognitive impairment, and age-related cognitive change. Furthermore, testing instruments should be sensitive to subtle changes in cognitive function over time.
National Institute on Aging-Alzheimer's Association: These organizations published criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in the criteria as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria. One is for core clinical criteria that can be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis. The second critieria is research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. The authors note that considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.
U.S. Preventive Services Task Force (USPSTF):
The USPSTF published a statement regarding screening for cognitive impairment in older adults. The statement concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for cognitive impairment (USPTF, 2014).
Centers for Medicare & Medicaid Services (CMS)
• 
Use Outside of the US European Federation of Neurological Societies (EFNS)
The EFNS published guidelines for the diagnosis and management of Alzheimer's disease (Hort, et al., 2010) . The guidelines note that, "Quantitative neuropsychological testing should be made in patients with questionable or very early Alzheimer's disease (AD)" (Level B).
Level B rating: (established as probably useful/predictive or not useful/predictive) requires at least one convincing class II study or overwhelming class III evidence.
The EFNS published clinical guidelines Clinical Management of Amyotrophic Lateral Sclerosis (MALS) (2012). Included in the recommendation is, "Those with evidence of early language deficits should undergo full neuropsychological testing (GCPP*)".
* GCPP: Where there was lack of evidence but consensus was clear, opinion stated as Good Clinical Practice Points
The EFNS published recommendations for the diagnosis of Parkinson's disease (PD) (Berardelli, et al., 2013 Grade B: A body of evidence including studies rated as 2++, directly applicable to the target population of the guideline and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+. 1++ :High quality meta-analyses, systematic reviews of clinical trials or high-quality clinical trials with a very low risk of bias. 1+ : Well-conducted meta-analyses, systematic reviews of clinical trials or well conducted clinical trials with a very low risk of bias. 2++ :High-quality systematic reviews of case control or cohort of studies. Well-conducted studies of case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal.
International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN):
A guideline prepared by the Commission on Neuropsychological Assessment of Hepatic Encephalopathy appointed by the ISHEN states that neuropsychological testing is an established methodology for quantifying cognitive impairment due to various forms of encephalopathy, including low-grade or minimal hepatic encephalopathy ).
National Institute for Health and Clinical Excellence (NICE) (United Kingdom [UK])
: NICE published clinical guidelines for diagnosis and management of the epilepsies in adults and children (2018). Regarding neuropsychological assessment, the guidelines note that:
• Neuropsychological assessment should be considered in children, young people and adults in whom it is important to evaluate learning disabilities and cognitive dysfunction, particularly in regard to language and memory.
• Referral for a neuropsychological assessment is indicated:  when a child, young person or adult with epilepsy is having educational or occupational difficulties  when an MRI has identified abnormalities in cognitively important brain regions  when a child, young person or adult complains of memory or other cognitive deficits and/or cognitive decline NICE published updated guidelines for dementia (2018 Tuberculosis neuritis A39. 81 Meningococcal encephalitis A44.0-A44.9
Systemic bartonellosis A50. 42 Late congenital syphilitic encephalitis A52.14 Late syphilitic encephalitis A68.0
Louse-borne relapsing fever A68.1
Tick-borne relapsing fever A68.9
Relapsing fever, unspecified A69. 20 Lyme disease, unspecified A69. 21 Meningitis due to Lyme disease A69.22
Other neurologic disorders in Lyme disease A75.0-A75.9
Typhus fever A77.0-A77. 9 Spotted fever (tick-borne rickettsioses) A78
Q fever A79.0 -A79.9 Other rickettsioses A81.00-A81.9 Atypical virus infections of the central nervous system caused by prions A83.0-A83. 9 Mosquito-borne viral encephalitis A84.0-A84. 9 Tick-borne viral encephalitis A85.0-A85. 8 Other viral encephalitis, not elsewhere classified A86
Unspecified viral encephalitis A88.0 Enteroviral exanthematous fever [Boston exanthem] A88. 8 Other specified viral infections of central nervous system A89 Unspecified viral infection of central nervous system A92. 31 West Nile virus infection with encephalitis B00.4
Herpesviral encephalitis B06.01
Rubella encephalitis B20
Human immunodeficiency virus [HIV] disease B26. 2 Mumps encephalitis B50.0-B50. 9 Plasmodium falciparum malaria B51.0-B51. 9 Plasmodium vivax malaria B52.0-B52. 9 Plasmodium malariae malaria B53.0 Plasmodium ovale malaria B53.1
Malaria due to simian plasmodia B53. 8 Other malaria, not elsewhere classified B54
Unspecified malaria B55.0-B55. 9 Leishmaniasis B56.0-B56. 9 African trypanosomiasis B57.0 Acute Chagas' disease with heart involvement B57.1 Acute Chagas' disease without heart involvement B57. 2 Chagas' disease (chronic) with heart involvement B57. 40-B57.49 Chagas' disease (chronic) with nervous system involvement B58. 2 Toxoplasma meningoencephalitis B60.0 Babesiosis B60. 8 Other specified protozoal diseases B64
Unspecified protozoal disease B90.0
Sequelae of central nervous system tuberculosis B91
Sequelae of poliomyelitis B94. 1 Sequelae of viral encephalitis C70.0-C70. 9 Malignant neoplasm of meninges C71.0-C71. 9 Malignant neoplasm of brain C72.0-C72. 9 Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system C79. 31 Secondary malignant neoplasm of brain C79. 32 Secondary malignant neoplasm of cerebral meninges D33.0-D33. 9 Benign neoplasm of brain and other parts of central nervous system D42.0
Neoplasm of uncertain behavior of cerebral meninges D43.0-D43. 9 Neoplasm of uncertain behavior of brain and central nervous system D49. 6 Neoplasm of unspecified behavior of brain F01.50-F01.51
Vascular dementia
F02. 80-F02.81 Dementia in other diseases classified elsewhere F03.90-F03.91
Unspecified dementia
F04
Amnestic disorder due to known physiological condition F05
Delirium due to known physiological condition F06.0-F06. 8 Other mental disorders due to known physiological condition F07. 81 Postconcussional syndrome F07.89
Other personality and behavioral disorders due to known physiological condition F07. 9 Unspecified personality and behavioral disorder due to known physiological condition F09
Unspecified mental disorder due to known physiological condition F10. 10 Shared psychotic disorder F25.0-F25. 9 Schizoaffective disorders F28
Other psychotic disorder not due to a substance or known physiological condition F29 Unspecified psychosis not due to a substance or known physiological condition F30.10-F30. 9 Manic episode F31.0-F31. 9 Bipolar disorder F32.0-F32. 9 Major depressive disorder, single episode F33.0-F33. 9 Major depressive disorder, recurrent F34.0-F34.9
Persistent mood [affective] disorders F39
Unspecified mood [affective] disorder F40.00-F40. 9 Phobic anxiety disorders F41.0-F41. 9 Other anxiety disorders F42.2-F42. 9 Obsessive-compulsive disorder F43.0-F43. 9 Reaction to severe stress, and adjustment disorders F44.0
Dissociative amnesia F44.1
Dissociative fugue F44. 2 Dissociative stupor F44. 4 Conversion disorder with motor symptom or deficit F44. 5 Conversion disorder with seizures or convulsions F44. 6 Conversion disorder with sensory symptom or deficit F44.7
Conversion disorder with mixed symptom presentation F45. 41 Pain disorder exclusively related to psychological factors F45. 42 Pain disorder with related psychological factors F53
Puerperal psychosis (Code invalid 10/1/2018) F53.0-F53. 1 Mental and behavioral disorders associated with the puerperium, not elsewhere classified F54
Psychological and behavioral factors associated with disorders or diseases classified elsewhere F64.0-F64. 9 Gender identity disorders F68. 10-F68.13 Factitious disorder imposed on self
F68.A Factitious disorder imposed on another F70-F79
Intellectual disabilities F80.0-F80. 9 Specific developmental disorders of speech and language F81.0-F81. 9 Specific developmental disorders of scholastic skills F82
Specific developmental disorder of motor function F84.0-F84. 9 Pervasive developmental disorders F88
Other disorders of psychological development F89
Unspecified disorder of psychological development F90.0-F90. 9 Attention-deficit hyperactivity disorders F91.0-F91. 9 Conduct disorders F93.0-F93. 9 Emotional disorders with onset specific to childhood F94.0-F94. 9 Disorders of social functioning with onset specific to childhood and adolescence F95.0-F95.9
Tic disorder F98. 8 Other specified behavioral and emotional disorders with onset usually occurring in childhood and adolescence F98. 9 Unspecified behavioral and emotional disorders with onset usually occurring in childhood and adolescence G00.0-G09 Bacterial meningitis, not elsewhere classified G10
Huntington's disease G13. 8 Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere G14
Postpolio syndrome G20
Parkinson's disease G21. 11 Neuroleptic induced parkinsonism G21. 19 Other drug induced secondary parkinsonism G21. 2 Secondary parkinsonism due to other external agents G21. 3 Postencephalitic parkinsonism G21.4 Vascular parkinsonism G21. 8 Other secondary parkinsonism G21. 9 Secondary parkinsonism, unspecified G23.0
Hallervorden-Spatz disease G23. 1 Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski] G23. 2 Striatonigral degeneration G23. 8 Other specified degenerative diseases of basal ganglia G23. 9 Degenerative disease of basal ganglia, unspecified G25.5
Other chorea G30.0-G30. 9 Alzheimer's disease G31.01
Pick's disease G31.09
Other frontotemporal dementia G31. 1 Senile degeneration of brain, not elsewhere classified G31.2 Degeneration of nervous system due to alcohol G31. 83 Dementia with Lewy bodies G31. 84 Mild cognitive impairment, so stated G31.85
Corticobasal degeneration G31.89
Other specified degenerative diseases of nervous system G31. 9 Degenerative disease of nervous system, unspecified G35
Multiple sclerosis G36.1
Acute and subacute hemorrhagic leukoencephalitis [Hurst] G36. 8 Other specified acute disseminated demyelination G36.9
Acute disseminated demyelination, unspecified G37.0
Diffuse sclerosis of central nervous system G37. 1 Central demyelination of corpus callosum G37. 2 Central pontine myelinolysis G37. 4 Subacute necrotizing myelitis of central nervous system G37. 8 Other specified demyelinating diseases of central nervous system G37. 9 Demyelinating disease of central nervous system, unspecified G40.001-G40. Obstructive hydrocephalus G91. 3 Post-traumatic hydrocephalus, unspecified G91. 4 Hydrocephalus in diseases classified elsewhere G91. 8 Other hydrocephalus G91. 9 Hydrocephalus, unspecified G92
Toxic encephalopathy G93.1 Anoxic brain damage, not elsewhere classified G93. 40 Encephalopathy, unspecified G93. 49 Other encephalopathy G93.7
Reye's syndrome G94
Other disorders of brain in diseases classified elsewhere G96.9
Disorder of central nervous system, unspecified G97. 2 Intracranial hypotension following ventricular shunting G97. 31-G97.32 Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a procedure G97. 81 Other intraoperative complications of nervous system G97. 82 Other postprocedural complications and disorders of nervous system I60.00-I60. 9 Nontraumatic subarachnoid hemorrhage I61.0-I61. 9 Nontraumatic intracerebral hemorrhage I62.00-I62. 9 Nontraumatic subdural hemorrhage I63.00-I63.9
Cerebral infarction I67. 3 Progressive vascular leukoencephalopathy I69.010-I69.019 Congenital malformation of brain, unspecified Q06.9
Congenital malformation of spinal cord, unspecified Q07.9
Congenital malformation of nervous system, unspecified Q28. Unspecified convulsions S06.0X0A
Concussion without loss of consciousness, initial encounter S06.0X0D
Concussion without loss of consciousness, subsequent encounter S06.0X0S Concussion without loss of consciousness, sequela S06.0X1A
Concussion with loss of consciousness of 30 minutes or less, initial encounter S06.0X1D
Concussion with loss of consciousness of 30 minutes or less, subsequent encounter S06.0X1S
Concussion with loss of consciousness of 30 minutes or less, sequela S06.0X9A
Concussion with loss of consciousness of unspecified duration, initial encounter S06.0X9D
Concussion with loss of consciousness of unspecified duration, subsequent encounter S06.0X9S
Concussion with loss of consciousness of unspecified duration, sequela S06.1X0S
Traumatic cerebral edema without loss of consciousness, sequela S06.1X1S
Traumatic cerebral edema with loss of consciousness of 30 minutes or less, sequela S06.1X2S
Traumatic cerebral edema with loss of consciousness of 31 minutes to 59 minutes, sequela S06.1X3S
Traumatic cerebral edema with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela S06.1X4S
Traumatic cerebral edema with loss of consciousness of 6 hours to 24 hours, sequela S06.1X5S
Traumatic cerebral edema with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela S06.1X6S
Traumatic cerebral edema with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela S06.1X9S
Traumatic cerebral edema with loss of consciousness of unspecified duration, sequela S06.2X0S
Diffuse traumatic brain injury without loss of consciousness, sequela S06.2X1S
Diffuse traumatic brain injury with loss of consciousness of 30 minutes or less, sequela S06.2X2S
Diffuse traumatic brain injury with loss of consciousness of 31 minutes to 59 minutes, sequela S06.2X3S
Diffuse traumatic brain injury with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela S06.2X4S
Diffuse traumatic brain injury with loss of consciousness of 6 hours to 24 hours, sequela S06.2X5S
Diffuse traumatic brain injury with loss of consciousness greater than 24 hours with return to pre-existing conscious levels, sequela S06.2X6S
Diffuse traumatic brain injury with loss of consciousness greater than 24 hours without return to pre-existing conscious level, sequela S06.2X9S
Diffuse traumatic brain injury with loss of consciousness of unspecified duration, sequela S06.300S
Unspecified focal traumatic brain injury without loss of consciousness, sequela S06.301S
Unspecified focal traumatic brain injury with loss of consciousness of 30 minutes or less, sequela S06.302S
Unspecified focal traumatic brain injury with loss of consciousness of 31 minutes to 59 minutes, sequela S06.303S
Unspecified focal traumatic brain injury with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela S06.304S
Unspecified focal traumatic brain injury with loss of consciousness of 6 hours to 24 hours, sequela S06.305S
Unspecified focal traumatic brain injury with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela S06.306S
Unspecified focal traumatic brain injury with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela S06.309S
Unspecified focal traumatic brain injury with loss of consciousness of unspecified duration, sequela S06.310S
Contusion and laceration of right cerebrum without loss of consciousness, sequela S06.311S
Contusion and laceration of right cerebrum with loss of consciousness of 30 minutes or less, sequela S06.312S
Contusion and laceration of right cerebrum with loss of consciousness of 31 minutes to 59 minutes, sequela S06.313S
Contusion and laceration of right cerebrum with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela S06.314S
Contusion and laceration of right cerebrum with loss of consciousness of 6 hours to 24 hours sequela S06.315S Contusion and laceration of right cerebrum with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela S06.316S
Contusion and laceration of right cerebrum with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela S06.319S
Contusion and laceration of right cerebrum with loss of consciousness of unspecified duration, sequela S06.320S
Contusion and laceration of left cerebrum without loss of consciousness, sequela S06.321S
Contusion and laceration of left cerebrum with loss of consciousness of 30 minutes or less, sequela S06.322S
Contusion and laceration of left cerebrum with loss of consciousness of 31 minutes to 59 minutes, sequela S06.323S
Contusion and laceration of left cerebrum with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela S06.324S
Contusion and laceration of left cerebrum with loss of consciousness of 6 hours to 24 hours sequela S06.325S
Contusion and laceration of left cerebrum with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela S06.326S
Contusion and laceration of left cerebrum with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela S06.329S
Contusion and laceration of left cerebrum with loss of consciousness of unspecified duration, sequel S06.330S
Contusion and laceration of cerebrum, unspecified, without loss of consciousness, sequela S06.331S
Contusion and laceration of cerebrum unspecified with loss of consciousness of 30 minutes or less, sequela S06.332S
Contusion and laceration of cerebrum unspecified with loss of consciousness of 31 minutes to 59 minutes, sequela S06.333S
Contusion and laceration of cerebrum unspecified with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela S06.334S
Contusion and laceration of cerebrum unspecified with loss of consciousness of 6 hours to 24 hours sequela S06.335S
Contusion and laceration of cerebrum unspecified with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela S06.336S
Contusion and laceration of cerebrum, unspecified, with loss of consciousness greater than 24 hours without return to pre-existing consciousness level with patient surviving, sequela S06.339S
Contusion and laceration of cerebrum, unspecified, with loss of consciousness of unspecified duration, sequela S06.340S Contusion, laceration and hemorrhage of cerebellum with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela S06.376S
Contusion, laceration and hemorrhage of cerebellum with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela S06.379S
Contusion, laceration and hemorrhage of cerebellum with loss of consciousness of unspecified duration, sequela S06.380S Contusion, laceration, and hemorrhage of brainstem without loss of consciousness, sequela S06.381S
Contusion, laceration and hemorrhage of brainstem with loss of consciousness of 30 minutes or less, sequela S06.382S
Contusion, laceration and hemorrhage of brainstem with loss of consciousness of 31 minutes to 59 minutes, sequela S06.383S
Contusion, laceration and hemorrhage of brainstem with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela S06.384S
Contusion, laceration and hemorrhage of brainstem with loss of consciousness of 6 hours to 24 hours sequela S06.385S
Contusion, laceration and hemorrhage of brainstem with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela S06.386S
Contusion, laceration and hemorrhage of brainstem with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela S06.389S Contusion, laceration and hemorrhage of brainstem with loss of consciousness of unspecified duration, sequela S06.4X0S
Epidural hemorrhage without loss of consciousness, sequela S06.4X1S
Epidural hemorrhage with loss of consciousness of 30 minutes or less, sequela S06.4X2S
Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela S06.4X3S
Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela S06.4X4S
Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours sequela S06.4X5S
Epidural hemorrhage with loss of consciousness greater than 24 hours with return to preexisting conscious level, sequela S06.4X6S
Epidural hemorrhage with loss of consciousness greater than 24 hours without return to preexisting conscious level with patient surviving, sequela S06.4X9S
Epidural hemorrhage with loss of consciousness of unspecified duration, sequela S06.5X0S
Traumatic subdural hemorrhage without loss of consciousness, sequela S06.5X1S
Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less, sequela S06.5X2S
Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela S06.5X3S
Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela S06.5X4S
Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours sequela S06.5X5S
Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela S06.5X6S
Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela S06.5X9S
Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, sequela S06.6X0S
Traumatic subarachnoid hemorrhage without loss of consciousness, sequela S06.6X1S
Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less, sequela S06.6X2S
Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela S06.6X3S
Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela S06.6X4S
Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours sequela S06.6X5S
Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela S06.6X6S
Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela S06.6X9S
Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration, sequela S06.810S Injury of right internal carotid artery, intracranial portion, not elsewhere classified without loss of consciousness, sequela S06.811S Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 30 minutes or less, sequela S06.812S Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 31 minutes to 59 minutes, sequela S06.813S
Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela S06.814S
Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 6 hours to 24 hours, sequela S06.815S
Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela S06.816S Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela S06.819S Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of unspecified duration, sequela S06.820S Injury of left internal carotid artery, intracranial portion, not elsewhere classified without loss of consciousness, sequela S06.821S Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 30 minutes or less, sequela S06.822S
Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 31 minutes to 59 minutes, sequela S06.823S
Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela S06.824S
Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 6 hours to 24 hours, sequela S06.825S
Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela S06.826S
Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela S06.829S
Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of unspecified duration, sequela S06.890S
Other specified intracranial injury without loss of consciousness, sequela S06.891S
Other specified intracranial injury with loss of consciousness of 30 minutes or less, sequela S06.892S
Other specified intracranial injury with loss of consciousness of 31 minutes to 59 minutes, sequela S06.893S
Other specified intracranial injury with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela S06.894S
Other specified intracranial injury with loss of consciousness of 6 hours to 24 hours, sequela S06.895S
Other specified intracranial injury with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela S06.896S
Other specified intracranial injury with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela S06.899S
Other specified intracranial injury with loss of consciousness of unspecified duration, sequela S06.9X0S
Unspecified intracranial injury without loss of consciousness, sequela S06.9X1S
Unspecified intracranial injury with loss of consciousness of 30 minutes or less, sequela S06.9X2S
Unspecified intracranial injury with loss of consciousness of 31 minutes to 59 minutes, sequela S06.9X3S
Unspecified intracranial injury with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela S06.9X4S
Unspecified intracranial injury with loss of consciousness of 6 hours to 24 hours sequela S06.9X5S
Unspecified intracranial injury with loss of consciousness greater than 24 hours with return to pre-existing consciousness level, sequela S06.9X6S
Unspecified intracranial injury with loss of consciousness greater than 24 hours without return to pre-existing consciousness level with patient surviving, sequela S06.9X9s
Unspecified intracranial injury with loss of consciousness of unspecified duration, sequela T66.XXXS Radiation sickness, unspecified, sequela 
